Arcutis Biotherapeutics, Inc. (ARQT) - 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025, for Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on immuno-dermatology. The company's portfolio centers on the ZORYVE franchise (roflumilast), which includes four FDA-approved products for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. During 2025, the company expanded its commercial footprint with new indications for ZORYVE foam (scalp and body psoriasis) and ZORYVE cream 0.05% (pediatric atopic dermatitis). The company also terminated its promotion agreement with Kowa Pharmaceuticals in January 2026, assuming full responsibility for primary care and pediatric sales.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $376.1 million | $196.5 million | +91% |
| Product Revenue (Net) | $372.1 million | $166.5 million | +123% |
| Net Loss | $(16.1) million | $(140.0) million | 88% Improvement |
| Operating Loss | $(12.2) million | $(128.4) million | 90% Improvement |
| Cash & Marketable Securities | $221.3 million | $228.6 million | As of Dec 31 |
| Long-Term Debt Outstanding | $100.0 million | $100.0 million | Principal Balance |
| Accumulated Deficit | $(1,138.1) million | $(1,121.9) million | N/A |
Revenue Breakdown (2025): ZORYVE foam ($181.9M), ZORYVE cream 0.3% ($121.0M), ZORYVE cream 0.15% ($68.3M), and ZORYVE cream 0.05% ($0.9M). Other revenue was $4.0M, primarily from milestone payments under the Huadong agreement.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 123% year-over-year, driven by the commercial launch of ZORYVE foam for scalp and body psoriasis (June 2025), ZORYVE cream 0.05% (October 2025), and continued growth in existing indications.
- Profitability Improvement: The net loss narrowed significantly from $140.0 million in 2024 to $16.1 million in 2025. This was due to revenue growth outpacing expense increases and a reduction in interest expense following a $100 million debt prepayment in October 2024.
- Expense Management: Research and Development (R&D) expenses remained flat at $77.1 million. Selling, General, and Administrative (SG&A) expenses increased by $45.2 million to $274.6 million, primarily due to expanded sales and marketing efforts.
- Debt Restructuring: In October 2024, the company prepaid $100 million of its term loan, reducing the outstanding principal to $100 million and lowering the interest rate structure. The company remains compliant with financial covenants.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- ZORYVE Expansion: The company is pursuing label expansions for ZORYVE cream 0.3% down to age 2 (PDUFA date June 2026) and ZORYVE cream 0.05% for infants (sNDA expected Q2 2026). Phase 2 trials for hidradenitis suppurativa and vitiligo are ongoing.
- ARQ-234: The company submitted an IND for ARQ-234 (a CD200R agonist) in July 2025 and anticipates commencing a Phase 1 study in Q1 2026.
- Commercial Strategy: Following the termination of the Kowa agreement, Arcutis will manage primary care and pediatric sales directly via a targeted internal team.
Key Risks and Contingencies:
- Patent Litigation: Arcutis is engaged in patent infringement litigation with Padagis regarding a generic version of ZORYVE cream 0.3%. The case is currently stayed, but the 30-month FDA stay on the generic ANDA is extended accordingly.
- Regulatory and Pricing: The company faces potential headwinds from the Inflation Reduction Act (IRA) and the "One Big Beautiful Bill Act" (enacted July 2025), which includes significant Medicaid funding reductions and potential price controls.
- Liquidity: While the company believes its capital resources ($221.3M cash/securities) are sufficient for at least 12 months, continued losses and milestone payment obligations (e.g., to AstraZeneca) require careful cash management.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the minimum net product revenue covenant (75% of projected revenue) under the SLR Investment Corp. loan agreement.
- Patent Status: Monitor the status of the Padagis litigation and the expiration of the 30-month stay on the generic ANDA for ZORYVE cream 0.3%.
- Regulatory Milestones: Track the PDUFA decision dates for ZORYVE cream 0.3% (age 2 expansion) and the sNDA submission for ZORYVE cream 0.05% (infant expansion).
- Reimbursement Impact: Assess the financial impact of the "One Big Beautiful Bill Act" on Medicaid reimbursement rates and patient enrollment.
- Commercial Execution: Evaluate the performance of the internal sales team following the termination of the Kowa promotion agreement.